{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-254571","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.238903+00:00","generated_at":"2026-05-17T01:44:37.447140+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyverna reports positive Phase 2 interim data for KYV-101 in gMG; 100% response rate","bullets":["100% (6/6) of patients achieved clinically meaningful reductions in MG-ADL and QMG at 24 weeks.","Mean reductions of -8.0 points (MG-ADL) and -7.7 points (QMG) from baseline; responses seen as early as 2 weeks.","No high-grade CRS or ICANS observed; one SAE of Grade 4 neutropenia resolved to Grade 1.","All patients free of nonsteroidal immunosuppressants, high-dose steroids, FcRn, and complement inhibitors.","Company plans to initiate Phase 3 portion of KYSA-6 trial by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-254571","json":"https://secwatch.observer/filing/0001193125-25-254571.json","markdown":"https://secwatch.observer/filing/0001193125-25-254571.md","text":"https://secwatch.observer/filing/0001193125-25-254571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/0001193125-25-254571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/d80007d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:44:37.447140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}